BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 70.93 Million EUR | -9.05% |
| 2022 | 77.99 Million EUR | 0.33% |
| 2021 | 77.73 Million EUR | 7.74% |
| 2020 | 72.15 Million EUR | 9.11% |
| 2019 | 66.12 Million EUR | -11.2% |
| 2018 | 74.46 Million EUR | 8.7% |
| 2017 | 68.5 Million EUR | 44.18% |
| 2016 | 47.51 Million EUR | 56.25% |
| 2015 | 30.4 Million EUR | 21.28% |
| 2014 | 25.07 Million EUR | -0.1% |
| 2013 | 25.09 Million EUR | 27.33% |
| 2012 | 19.71 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 73.24 Million EUR | 10.2% |
| 2024 Q1 | 66.47 Million EUR | -6.3% |
| 2024 Q3 | 74.14 Million EUR | 1.23% |
| 2023 Q3 | 69.48 Million EUR | -6.75% |
| 2023 Q4 | 70.93 Million EUR | 2.09% |
| 2023 FY | 70.93 Million EUR | -9.05% |
| 2023 Q1 | 75.53 Million EUR | -3.15% |
| 2023 Q2 | 74.51 Million EUR | -1.35% |
| 2022 Q3 | 77.9 Million EUR | -4.57% |
| 2022 Q2 | 81.63 Million EUR | 7.08% |
| 2022 Q1 | 76.23 Million EUR | -1.93% |
| 2022 FY | 77.99 Million EUR | 0.33% |
| 2022 Q4 | 77.99 Million EUR | 0.11% |
| 2021 FY | 77.73 Million EUR | 7.74% |
| 2021 Q2 | 67.14 Million EUR | -0.33% |
| 2021 Q3 | 60.08 Million EUR | -10.51% |
| 2021 Q4 | 77.73 Million EUR | 29.37% |
| 2021 Q1 | 67.36 Million EUR | -6.63% |
| 2020 Q2 | 64.8 Million EUR | -7.96% |
| 2020 Q3 | 75.73 Million EUR | 16.87% |
| 2020 Q4 | 72.15 Million EUR | -4.73% |
| 2020 FY | 72.15 Million EUR | 9.11% |
| 2020 Q1 | 70.41 Million EUR | 6.48% |
| 2019 Q3 | 60.07 Million EUR | -13.81% |
| 2019 FY | 66.12 Million EUR | -11.2% |
| 2019 Q4 | 66.12 Million EUR | 10.07% |
| 2019 Q2 | 69.7 Million EUR | -4.02% |
| 2019 Q1 | 72.61 Million EUR | -2.48% |
| 2018 Q3 | 78.83 Million EUR | 9.22% |
| 2018 Q4 | 74.46 Million EUR | -5.55% |
| 2018 FY | 74.46 Million EUR | 8.7% |
| 2018 Q1 | 66.09 Million EUR | -3.52% |
| 2018 Q2 | 72.18 Million EUR | 9.22% |
| 2017 FY | 68.5 Million EUR | 44.18% |
| 2017 Q1 | 45.69 Million EUR | -3.83% |
| 2017 Q2 | 43.56 Million EUR | -4.65% |
| 2017 Q3 | 41.27 Million EUR | -5.26% |
| 2017 Q4 | 68.5 Million EUR | 65.95% |
| 2016 FY | 47.51 Million EUR | 56.25% |
| 2016 Q4 | 47.51 Million EUR | -1.14% |
| 2016 Q2 | 50.69 Million EUR | 67.07% |
| 2016 Q1 | 30.34 Million EUR | -0.21% |
| 2016 Q3 | 48.05 Million EUR | -5.19% |
| 2015 Q4 | 30.4 Million EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 FY | 30.4 Million EUR | 21.28% |
| 2014 FY | 25.07 Million EUR | -0.1% |
| 2013 FY | 25.09 Million EUR | 27.33% |
| 2012 FY | 19.71 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 99.692% |
| CureVac N.V. | 788.89 Million EUR | 91.008% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 95.088% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 95.088% |
| Formycon AG | 890.36 Million EUR | 92.033% |
| Heidelberg Pharma AG | 70.35 Million EUR | -0.83% |
| Medigene AG | 31.71 Million EUR | -123.663% |